ArticleThe Pediatric infectious disease journal2026
Reliability of RSV Antigen Diagnostic Tests in the Presence of Nirsevimab.
Article in The Pediatric infectious disease journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNirsevimab is approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Although nucleic acid detection by polymerase chain reaction is primarily utilized for the clinical diagnosis of RSV, antigen detection is still routinely used and primarily relies on direct interaction with the RSV F protein in patient nasal samples. While expected monoclonal antibody (mAb) levels in nasal samples are typically <1 μg/mL following administration, some mAbs targeting the RSV F protein, such as palivizumab, have been shown to interfere with antigen detection. We assessed whether the presence of nirsevimab in nasal samples may interfere with RSV detection by antigen tests.
methodsRSV detection was evaluated in 6 antigen detection tests utilizing contrived samples containing RSV A or B, and nirsevimab at 2 concentrations (1 or 10 µg/mL) chosen to estimate and exceed physiologically relevant concentrations. To better simulate real-world diagnostic specimens, RSV-positive nasal samples were pooled and assessed in the presence of nirsevimab in 2 frequently utilized detection tests.
resultsRSV was detected in contrived samples by all diagnostic kits evaluated in the presence of nirsevimab at both concentrations. Furthermore, RSV was detected in all nasal specimen pools by both diagnostic tests and remained detectable in the presence of nirsevimab at both concentrations tested, displaying 100% agreement with nonspiked pools.
conclusionsNirsevimab did not interfere with RSV detection with any of the antigen tests evaluated, suggesting patients who receive nirsevimab are unlikely to require alternative assays for clinical RSV diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.